Abstract:Prostate cancer (PrCa) is characterized by progression from an androgen-dependent phenotype to one that is inevitably androgen independent (AI) and lethal. Recent evidence strongly suggests that the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) and androgen receptor (AR) signalling pathways provide prostatic epithelium with the necessary signalling events to escape the apoptotic response associated with androgen withdrawal therapy. Silencing of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and glycogen synthase kinase β (GSK3 β ) are frequently associated with advanced PrCa systems and likely serve critical roles in promoting AR and PI3K/Akt gain-of-function. That PTEN negatively regulates AR and is sufficient to promote metastatic PrCa in murine models strongly implies its role as a gatekeeper of progressive PrCa. In human PrCa, PTEN loss is correlated with substantial increases in Akt Ser473 and integrin-linked kinase expression, both of which promote Ser 9 phospho-inhibition of GSK3 β and inactivation of apoptotic factors. Sufficient evidence also suggests that GSK3 β is not only a critical regulator of proproliferative signalling but also a promiscuous one as PI3K/Akt pools of GSK3 β are, at least in part, functionally interchangeable with those of the Wnt/ β -catenin pathway. Thus, GSK3 β may serve not only as a mediator of PI3K/Akt activation but may also regulate the potent transactivation and proproliferative effects that Wnt3a and β -catenin confer upon AR. These data suggest that prostate-specific activation of GSK3 β may serve as a viable pharmacological option. Thus, in this review, we emphasize that temporal changes in GSK3 β and PTEN expression during progression to AI PrCa are important factors when considering the potential for therapies targeting the oncogenic contributions of PI3K/Akt and AR signalling pathways.

Important Roles of PI3K/AKT Signaling Pathway and Relevant Inhibitors in Prostate Cancer Progression

Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer

Targeting PI3K/Akt signaling in prostate cancer therapy

The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance

Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?

PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.

PTEN and GSK3 Β : Key Regulators of Progression to Androgen-Independent Prostate Cancer

Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target

Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention

Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-Kinase.

Targeting PI3K in cancer: mechanisms and advances in clinical trials

PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis

Targeting PI3K/Akt signal transduction for cancer therapy

Advances in Subunits of PI3K Class I in Cancer.

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets